Cover

Controversies in the Treatment of Lung Cancer

12th International Symposium on Special Aspects of Radiotherapy, Berlin, October 2008

Editor(s): Heide J. (Berlin) 
Schmittel A. (Berlin) 
Kaiser D. (Berlin) 
Hinkelbein W. (Berlin) 
Table of Contents
Vol. 42, No. , 2010
Section title: NSCLC: Stage I/II Disease
Heide J, Schmittel A, Kaiser D, Hinkelbein W (eds): Controversies in the Treatment of Lung Cancer. Front Radiat Ther Oncol. Basel, Karger, 2010, vol 42, pp 87–93
(DOI:10.1159/000262464)

Radiation Therapy for Early Stage (I/II) Non-Small Cell Lung Cancer

Jeremic B. · Casas F. · Wang L. · Perin B.
aDivision of Human Health (NAHU), Applied Radiobiology and Radiotherapy (ARBR) Section, International Atomic Energy Agency (IAEA), Vienna, Austria; bDepartment of Radiation Oncology, University Clinic, Barcelona, Spain; cChinese Medical Academy of Sciences, Beijing, China; dInstitute of Lung Disease, Sremska Kamenica, Serbia

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 33.00
Account: USD 23.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select


Article / Publication Details

First-Page Preview
Abstract of NSCLC: Stage I/II Disease

Published online: 11/24/2009
Cover Date: 2010

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9298-7 (Print)
eISBN: 978-3-8055-9299-4 (Online)

Abstract

For patients with early (stage I/II) non-small cell lung cancer (NSCLC) surgery is considered as the standard treatment of choice, although recent data on additional chemotherapy (CHT) showed that it may be beneficial in this setting. There is, however, a subset of patients that never undergo surgery. These patients are considered technically operable, but medically inoperable, due to existing comorbidities. In addition, frequently elderly patients with early NSCLC are denied surgery due to expected peri- and/or postoperative complications. Finally, in recent years there has been an increase in the incidence of patients refusing surgery. For all these patients, radiation therapy (RT) was traditionally considered as the standard treatment option. Data accumulated over the last 5 decades showed that RT alone can produce median survival times of up to > 30 months and 5-year survival of up to 30%. When cancer-unrelated deaths were taken into account, cause-specific survival rates were usually higher for some 10–15%. Accumulated experience seems to suggest that doses of at least 65 Gy with standard fractionation or its equivalent when altered fractionation is used are necessary for control of the disease. Smaller tumors seem to have favorable prognosis, while the issue of elective nodal RT continues to be controversial. Patterns of failure have clearly identified local failure as the predominant one. Although a number of potential pretreatment patient- and tumor-related prognostic factors have been examined, none has been shown to clearly influenced survival. Toxicity was usually low.


  

Author Contacts

Branislav Jeremic, MD, PhD, Institute of Lung Disease, Institutski put 4, RS-21204 Sremska Kamenica (Serbia), Tel. +381 65 4146663, E-Mail nebareje@gmail.com

  

Article Information

Number of Print Pages : 7

  

Publication Details

Book Serie: Frontiers of Radiation Therapy and Oncology, Vol. 42, Year 2010

Editor(s): Heide, J. (Berlin); Schmittel, A. (Berlin); Kaiser, D. (Berlin); Hinkelbein, W. (Berlin)
ISSN: 0071-9676 (Print), eISSN: 1662-3789 (Online)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=0071-9676

Book Title: Controversies in the Treatment of Lung Cancer (12th International Symposium on Special Aspects of Radiotherapy, Berlin, October 2008)

Editor(s): Heide J, Schmittel A, Kaiser D, Hinkelbein W (eds)

For additional information:
http://content.karger.com/ProdukteDB/produkte.asp?issn=0071-9676&volume=42


Article / Publication Details

First-Page Preview
Abstract of NSCLC: Stage I/II Disease

Published online: 11/24/2009
Cover Date: 2010

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9298-7 (Print)
eISBN: 978-3-8055-9299-4 (Online)


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.